Unleashing the potential of mRNA: Overcoming delivery challenges with nanoparticles

被引:0
作者
Chen, Qiang [1 ]
Huo, Ku-Geng [2 ]
Ji, Sheng-Min [3 ]
Pang, Shu-De [4 ]
Sun, Tian-Ying [3 ]
Niu, Yi [1 ]
Jiang, Zi-Hao [1 ]
Zhang, Peng [3 ]
Han, Shu-Xin [1 ]
Li, Jin-Yao [1 ]
机构
[1] Xinjiang Univ, Coll Life Sci & Technol, Xinjiang Key Lab Biol Resources & Genet Engn, Urumqi 830046, Peoples R China
[2] Cyagen Biosci Guangzhou Inc, Guangzhou, Guangdong, Peoples R China
[3] Yantai Univ, Key Lab Mol Pharmacol & Drug Evaluat, Collaborat Innovat Ctr Adv Drug Delivery Syst & Bi, Sch Pharm,Minist Educ, Yantai 264005, Peoples R China
[4] Qingdao Univ, Sch Pharm, Dept Pharmaceut, Qingdao, Peoples R China
关键词
delivery strategy; mRNA; nanomaterial; nanotechnology; VIRUS-LIKE PARTICLES; IN-VIVO DELIVERY; GENE-THERAPY; LIPID NANOPARTICLES; NONVIRAL VECTORS; SURFACE MODIFICATION; CANCER; VACCINES; STRATEGIES; THERAPEUTICS;
D O I
10.1002/btm2.10713
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Messenger RNA (mRNA) has emerged as a promising therapeutic strategy for various diseases, including cancer, infectious diseases, and genetic disorders. The mRNA-based therapeutics have gained significant attention due to their ability to regulate targeted cells, activate immune cells, and avoid potential risks associated with DNA-based technology. However, the clinical application of mRNA in cancer therapy is hindered by the instability of RNA, physiological barriers, and the risk of immunogenic hurdles. To overcome these challenges and ensure the safe delivery of mRNA therapeutics to target sites, nanoparticle-based delivery systems have been explored as potential tools in vitro and in vivo applications. This review provides a comprehensive overview of the current status of mRNA therapy, discussing its advantages and limitations, delivery strategies and materials, as well as applications in different fields. By exploring these aspects, the researcher can gain a more complete understanding of the current state, prospects, and challenges of mRNA technologies.
引用
收藏
页数:15
相关论文
共 140 条
[1]   Synthesis and surface modification of mesoporous silica nanoparticles and its application as carriers for sustained drug delivery [J].
Ahmadi, Ebrahim ;
Dehghannejad, Nematollah ;
Hashemikia, Samaneh ;
Ghasemnejad, Merajaddin ;
Tabebordbar, Hashem .
DRUG DELIVERY, 2014, 21 (03) :164-172
[2]   Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial [J].
Alberer, Martin ;
Gnad-Vogt, Ulrike ;
Hong, Henoch Sangjoon ;
Mehr, Keyvan Tadjalli ;
Backert, Linus ;
Finak, Greg ;
Gottardo, Raphael ;
Bica, Mihai Alexandru ;
Garofano, Aurelio ;
Koch, Sven Dominik ;
Fotin-Mleczek, Mariola ;
Hoerr, Ingmar ;
Clemens, Ralf ;
von Sonnenburg, Frank .
LANCET, 2017, 390 (10101) :1511-1520
[3]  
[Anonymous], 2021, FDA Approves First COVID-19 Vaccine
[4]   In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles [J].
Arami, Hamed ;
Khandhar, Amit ;
Liggitt, Denny ;
Krishnan, Kannan M. .
CHEMICAL SOCIETY REVIEWS, 2015, 44 (23) :8576-8607
[5]   Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings [J].
Au, Hau Kiu Edna ;
Isalan, Mark ;
Mielcarek, Michal .
FRONTIERS IN MEDICINE, 2022, 8
[6]   Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins [J].
Banskota, Samagya ;
Raguram, Aditya ;
Suh, Susie ;
Du, Samuel W. ;
Davis, Jessie R. ;
Choi, Elliot H. ;
Wang, Xiao ;
Nielsen, Sarah C. ;
Newby, Gregory A. ;
Randolph, Peyton B. ;
Osborn, Mark J. ;
Musunuru, Kiran ;
Palczewski, Krzysztof ;
Liu, David R. .
CELL, 2022, 185 (02) :250-+
[7]   Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study [J].
Barda, Noam ;
Dagan, Noa ;
Cohen, Cyrille ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Kohane, Isaac S. ;
Reis, Ben Y. ;
Balicer, Ran D. .
LANCET, 2021, 398 (10316) :2093-2100
[8]   A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity [J].
Beissert, Tim ;
Perkovic, Mario ;
Vogel, Annette ;
Erbar, Stephanie ;
Walzer, Kerstin C. ;
Hempel, Tina ;
Brill, Silke ;
Haefner, Erik ;
Becker, Rene ;
Tureci, Ozlem ;
Sahin, Ugur .
MOLECULAR THERAPY, 2020, 28 (01) :119-128
[9]   mRNA therapeutics: beyond vaccine applications [J].
Bhat, Balkrishen ;
Karve, Shrirang ;
Anderson, Daniel G. .
TRENDS IN MOLECULAR MEDICINE, 2021, 27 (09) :923-924
[10]   Degradable polymer-coated gold nanoparticles for co-delivery of DNA and siRNA [J].
Bishop, Corey J. ;
Tzeng, Stephany Y. ;
Green, Jordan J. .
ACTA BIOMATERIALIA, 2015, 11 :393-403